Bliss GVS Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bliss GVS Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹55 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier. More money tied up than 95% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 47.4 times by its yearly operating cash. Higher than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹120Over the last 3 years, every ₹100 of reported profit came with ₹120 of operating cash.
Higher than 56% of Healthcare companies in India.
Self-Funding Ratio
2.2×Over the last 3 years its own operating cash covered its investment spending (capex) 2.2 times.
Higher than 69% of Healthcare companies in India.
Cash Locked Ratio
₹55For every ₹100 of sales, ₹55 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier.
More money tied up than 95% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹34Sales grew 23% in 3 years; of every extra ₹100 of sales, ₹34 became extra profit.
Higher than 82% of Healthcare companies in India.
Asset Productivity Ratio
+23% / +29%In 3 years sales changed by +23% while total assets changed by +29%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
47.4×Debt due within a year is covered 47.4 times by its yearly operating cash.
Higher than 92% of Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 72% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 67% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 69% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bliss GVS Pharma Limited owes ₹0.17 for every ₹1 it owns. Net profit rose 53% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
51.0Investors pay ₹51.0 for every ₹1 of Bliss GVS Pharma Limited's yearly profit, higher than 71% of Healthcare companies in India.
P/B ratio
5.73The share price is 5.73 times Bliss GVS Pharma Limited's book value per share, higher than 64% of Healthcare companies in India.
Market cap
₹6,834 CrThe total market value of all of Bliss GVS Pharma Limited's shares at today's price (share price × number of shares), larger than 56% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,193 CrWhat Bliss GVS Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹112.19Net worth divided by the number of shares. The share price of ₹642.70 is 5.7 times this, which is the P/B above.
Return on equity (ROE)
11.2%Bliss GVS Pharma Limited earned 11.2% on its shareholders' money over the last year, lower than 60% of Healthcare companies in India.
Owes vs Owns
0.17×Bliss GVS Pharma Limited owes ₹0.17 for every ₹1 it owns (low), lower than 85% of Healthcare companies in India.
Dividend yield
0.23%Bliss GVS Pharma Limited pays 0.23% of its share price as dividends a year, lower than 67% of dividend-paying Healthcare companies in India.
Revenue growth
+15%Revenue rose 15% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
+53%Net profit rose 53% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Profit margin
14.0%Bliss GVS Pharma Limited keeps ₹14 of every ₹100 of revenue as net profit.
Cash quality
1.07×Cash from Bliss GVS Pharma Limited's business was 1.07× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
42.9×Bliss GVS Pharma Limited's operating profit covered its interest costs 42.9 times in the year to Mar 2026.
Cash vs debt
Net cashBliss GVS Pharma Limited held ₹167 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Bliss GVS Pharma Limited's P/E ratio?
Investors pay ₹51.0 for every ₹1 of Bliss GVS Pharma Limited's yearly profit, higher than 71% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bliss GVS Pharma Limited: ₹6,834 Cr ÷ ₹1,193 Cr (31 Mar 2026) = 5.7.
What is Bliss GVS Pharma Limited's return on equity?
Bliss GVS Pharma Limited earned 11.2% on its shareholders' money over the last year, lower than 60% of Healthcare companies in India.
How much does Bliss GVS Pharma Limited owe compared with what it owns?
Bliss GVS Pharma Limited owes ₹0.17 for every ₹1 it owns (low), lower than 85% of Healthcare companies in India.
Does Bliss GVS Pharma Limited pay a dividend?
Yes. Bliss GVS Pharma Limited pays 0.23% of its share price as dividends a year, lower than 67% of dividend-paying Healthcare companies in India.
Is Bliss GVS Pharma Limited's revenue growing?
Revenue rose 15% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.